|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cancer statistics. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html.
Accessed June 30 2022 Cancer Information Service, Natl Cancer Cntr,
Japan. Vital Statistics of Japan Ministry of Health, Labour and
Welfare.
|
|
3
|
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang
W, Zhang H and Li Z: Diabetes mellitus and risk of pancreatic
cancer: A meta-analysis of cohort studies. Eur J Cancer.
47:1928–1937. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Stolzenberg-Solomon RZ, Adams K, Leitzmann
M, Schairer C, Michaud DS, Hollenbeck A, Schatzkin A and Silverman
DT: Adiposity, physical activity, and pancreatic cancer in the
National Institutes of Health-AARP Diet and Health Cohort. Am J
Epidemiol. 167:586–597. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Aune D, Greenwood DC, Chan DS, Vieira R,
Vieira AR, Navarro Rosenblatt DA, Cade JE, Burley VJ and Norat T:
Body mass index, abdominal fatness and pancreatic cancer risk: A
systematic review and non-linear dose-response meta-analysis of
prospective studies. Ann Oncol. 23:843–852. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Matsuo K, Ito H, Wakai K, Nagata C, Mizoue
T, Tanaka K, Tsuji I, Tamakoshi A, Sasazuki S, Inoue M, et al:
Cigarette smoking and pancreas cancer risk: An evaluation based on
a systematic review of epidemiologic evidence in the Japanese
population. Jpn J Clin Oncol. 41:1292–1302. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tramacere I, Scotti L, Jenab M, Bagnardi
V, Bellocco R, Rota M, Corrao G, Bravi F, Boffetta P and La Vecchia
C: Alcohol drinking and pancreatic cancer risk: A meta-analysis of
the dose-risk relation. Int J Cancer. 126:1474–1486.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Raimondi S, Lowenfels AB, Morselli-Labate
AM, Maisonneuve P and Pezzilli R: Pancreatic cancer in chronic
pancreatitis; aetiology, incidence, and early detection. Best Pract
Res Clin Gastroenterol. 24:349–358. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ueno H, Okusaka T, Ikeda M, Takezako Y and
Morizane C: An early phase II study of S-1 in patients with
metastatic pancreatic cancer. Oncology. 68:171–178. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Okusaka T, Funakoshi A, Furuse J, Boku N,
Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for
metastatic pancreatic cancer. Cancer Chemother Pharmacol.
61:615–621. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: Folfirinox versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Okusaka T, Ikeda M, Fukutomi A, Ioka T,
Furuse J, Ohkawa S, Isayama H and Boku N: Phase II study of
FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic
pancreatic cancer. Cancer Sci. 105:1321–1326. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M,
Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, et al: A phase II
study of modified folfirinox for chemotherapy-naïve patients with
metastatic pancreatic cancer. Cancer Chemother Pharmacol.
81:1017–1023. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
National Comprehensive Cancer Network
(NCCN): NCCN clinical practice guidelines in oncology pancreatic
adenocarcinoma. Version 1.2022. https://www.nccn.org/guidelines/category_1. Accessed
June 30, 2022.
|
|
19
|
Okusaka T, Nakamura M, Yoshida M, Kitano
M, Uesaka K, Ito Y, Furuse J, Hanada K and Okazaki K: Committee for
Revision of Clinical Guidelines for Pancreatic Cancer of the Japan
Pancreas Society. Clinical practice guidelines for pancreatic
cancer 2019 from the Japan Pancreas Society: A synopsis. Pancreas.
49:326–335. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang-Gillam A, Hubner RA, Siveke JT, Von
Hoff DD, Belanger B, de Jong FA, Mirakhur B and Chen LT: NAPOLI-1
phase 3 study of liposomal irinotecan in metastatic pancreatic
cancer: Final overall survival analysis and characteristics of
long-term survivors. Eur J Cancer. 108:78–87. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Golan T, Hammel P, Reni M, Van Cutsem E,
Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Maintenance olaparib for germline BRCA-mutated metastatic
pancreatic cancer. N Engl J Med. 381:317–327. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Averitt AJ, Weng C, Ryan P and Perotte A:
Translating evidence into practice: Eligibility criteria fail to
eliminate clinically significant differences between real-world and
study populations. NPJ Digit Med. 3(67)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hilgers RD, König F, Molenberghs G and
Senn S: Design and analysis of clinical trials for small rare
disease populations. J Rare Dis Res Treat. 1:53–60. 2016.
|
|
24
|
Latimer NR: Survival analysis for economic
evaluations alongside clinical trials-extrapolation with
patient-level data: Inconsistencies, limitations, and a practical
guide. Med Decis Making. 33:743–754. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Corrigan-Curay J, Sacks L and Woodcock J:
Real-world evidence and real-world data for evaluating drug safety
and effectiveness. JAMA. 320:867–868. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Katkade VB, Sanders KN and Zou KH: Real
world data: An opportunity to supplement existing evidence for the
use of long-established medicines in health care decision making. J
Multidiscip Healthc. 11:295–304. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Makady A, de Boer A, Hillege H, Klungel O
and Goettsch W: (on behalf of GetReal Work Package 1). What is
real-world data? A review of definitions based on literature and
stakeholder interviews. Value Health. 20:858–865. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shimoyama R, Imamura Y, Uryu K, Mase T,
Fujimura Y, Hayashi M, Ohtaki M, Ohtani K, Shinozaki N and Minami
H: Real-world outcomes of systemic therapy in Japanese patients
with cancer (Tokushukai REAl-world Data project: TREAD): Study
protocol for a nationwide cohort study. Healthcare (Basel).
10(2146)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
National Cancer Registry (Ministry of
Health, Labour and Welfare) tabulated by Cancer Information
Service, National Cancer Center, Japan. https://ganjoho.jp/med_pro/cancer_control/can_reg/index.html.
Accessed June 30, 2022.
|
|
30
|
Haj Mohammad N, Bernards N, Besselink MG,
Busch OR, Wilmink JW, Creemers GJ, De Hingh IH, Lemmens VE and van
Laarhoven HW: Volume matters in the systemic treatment of
metastatic pancreatic cancer: A population-based study in the
Netherlands. J Cancer Res Clin Oncol. 142:1353–1360.
2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Terashima T, Yamashita T, Sakai A, Ohta H,
Hinoue Y, Toya D, Kawai H, Yonejima M, Urabe T, Noda Y, et al:
Treatment patterns and outcomes of unresectable pancreatic cancer
patients in real-life practice: A region-wide analysis. Jpn J Clin
Oncol. 48:966–973. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sasaki T, Kanata R, Yamada I, Matsuyama M,
Ozaka M and Sasahira N: Improvement of treatment outcomes for
metastatic pancreatic cancer: A real-world data analysis. In Vivo.
33:271–276. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Javed MA, Beyer G, Le N, Vinci A, Wong H,
Palmer D, Morgan RD, Lamarca A, Hubner RA, Valle JW, et al: Impact
of intensified chemotherapy in metastatic pancreatic ductal
adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology.
19:97–104. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cho IR, Kang H, Jo JH, Lee HS, Chung MJ,
Park JY, Park SW, Song SY, An C, Park MS and Bang S: Folfirinox vs
gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic
cancer: Single-center cohort study. World J Gastrointest Oncol.
12:182–194. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chan KKW, Guo H, Cheng S, Beca JM,
Redmond-Misner R, Isaranuwatchai W, Qiao L, Earle C, Berry SR,
Biagi JJ, et al: Real-world outcomes of FOLFIRINOX vs gemcitabine
and nab-paclitaxel in advanced pancreatic cancer: A
population-based propensity score-weighted analysis. Cancer Med.
9:160–169. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Franco F, Camara JC, Martín-Valadés JI,
López-Alfonso A, Marrupe D, Gutiérrez-Abad D, Martínez-Amores B,
León A, Juez I, Pérez M, et al: Clinical outcomes of folfirinox and
gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the
real world setting. Clin Transl Oncol. 23:812–819. 2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pijnappel EN, Dijksterhuis WPM, van der
Geest LG, de Vos-Geelen J, de Groot JWB, Homs MYV, Creemers GJ,
Mohammad NH, Besselink MG, van Laarhoven HWM, et al: First- and
second-line palliative systemic treatment outcomes in a real-world
metastatic pancreatic cancer cohort. J Natl Compr Canc Netw.
20:443–450.e3. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Mizusawa J, Ohba A, Ozaka M, Katayama H,
Okusaka T, Kobayashi S, Ikeda M, Terashima T, Sasahira N, Okano N,
et al: Protocol of a randomized phase II/III study of gemcitabine
plus nab-paclitaxel combination therapy versus modified FOLFIRINOX
versus S-IROX for metastatic or recurrent pancreatic cancer:
JCOG1611 (GENERATE). Jpn J Clin Oncol. 53:80–84. 2023.
|
